Form 8-K

8-K — IDEXX LABORATORIES INC /DE

Accession: 0001104659-26-090033

Filed: 2026-08-04

Period: 2026-08-04

CIK: 0000874716

SIC: 2835 (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tm2622041d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2622041d1_ex99-1.htm)

GRAPHIC (tm2622041d1_8kimg01.jpg)

GRAPHIC (tm2622041d1_ex99-1img01.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2622041d1_8k.htm · Sequence: 1

false

IDEXX LABORATORIES INC /DE

0000874716

2026-08-04

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 4, 2026

IDEXX LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Delaware

000-19271

01-0393723

(State or other jurisdiction

(Commission File Number)

(IRS Employer Identification No.)

of incorporation)

One IDEXX Drive, Westbrook, Maine

04092

(Address of principal executive offices)

(ZIP Code)

207.556.0300

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction

A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.10 par value per share

IDXX

NASDAQ Global Select Market

Indicate by

check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

If an emerging

growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any

new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On August 4, 2026, IDEXX Laboratories, Inc.

(the “Company”) announced its financial results for the quarter ended June 30, 2026. The full text of the press release

issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with general instructions to Form 8-K,

the information in this Form 8-K and the Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not be deemed

“filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise

subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of

1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit relating to Item

2.02 shall be deemed to be furnished, and not filed.

Exhibit No.

Description

of Exhibit

99.1 Press Release entitled “IDEXX Laboratories Announces Second Quarter Results,” issued by the

Company on August 4, 2026.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IDEXX LABORATORIES, INC.

Date: August 4, 2026

By:

/s/ Andrew Emerson

Andrew Emerson

Executive Vice President,

Chief Financial Officer and Treasurer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2622041d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

IDEXX

Laboratories Announces Second Quarter Results

▪ Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as

reported and 10% organic.

▪ Strong volume-driven CAG Diagnostics recurring revenue growth including benefits from IDEXX's innovations and expansion of diagnostics

utilization.

▪ IDEXX inVue Dx™ installed base surpasses 9,000 instruments, supported by over 1,600 placements during the quarter.

▪ Drives EPS of $4.27, an increase of 18% as reported and 15% on a comparable basis, with operating margin up 140 basis points as

reported and 110 basis points on a comparable basis.

▪ Narrows 2026 revenue guidance to $4,700 million - $4,745 million, up $5 million at midpoint, reflecting benefit of CAG Diagnostics

recurring revenue performance, and net of $15 million headwind from updated foreign exchange estimates.

▪ Raises midpoint for 2026 reported revenue growth outlook to 9.7%, reflecting a range of 9.1% - 10.3%, and CAG Diagnostics recurring

revenue reported growth of 10.1% - 11.3%, with projected 2026 organic revenue growth of 8.5% - 9.7% and CAG Diagnostics recurring revenue

organic growth of 9.5% - 10.7%.

▪ Increases 2026 EPS outlook to $14.69 - $14.94, reflecting an increase of $0.14 compared to prior guidance midpoint, supported by

a raised revenue outlook at midpoint while advancing incremental investments aligned with commercial and innovation priorities.

WESTBROOK,

Maine, August 4, 2026— IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation,

today announced second quarter results.

Second Quarter Results

The Company reports revenues of $1,217 million for the second quarter

of 2026, an increase of 10% as reported and 9% organic, driven by Companion Animal Group ("CAG") growth of 9% as reported and

organic, Water revenue growth of 15% as reported and 13% organic, and LPD revenue growth of 11% as reported and 9% organic.

Second quarter earnings per diluted share (“EPS”) were

$4.27, an increase of 18% as reported and 15% on a comparable basis. Second quarter EPS included $0.14 per share in tax benefits from

share-based compensation and $0.06 per share benefit from year-over-year currency changes.

IDEXX Announces Second Quarter Results

August 4, 2026

Page 2 of 17

“Our second quarter results reflect the strength of our Technology

for Life strategy, with continued innovation across our Catalyst, Fecal Dx, and IDEXX inVue Dx platforms supporting deeper customer adoption

and higher diagnostic utilization,” said Mike Erickson, President and Chief Executive Officer. “This is the kind of durable,

compounding growth we're building for the long term, helping veterinarians see more and do more for their patients while creating lasting

value for our shareholders.”

Second Quarter Performance Highlights

Companion Animal Group (“CAG”)

CAG revenue growth was led by CAG Diagnostics recurring revenue growth

of 11% as reported and 10% organic, including 14% reported and 12% organic gains in International regions, and 10% reported and organic

growth in the U.S., outpacing sector growth levels.

Additional

U.S. companion animal practice key metrics are available in the Q2 2026 Earnings Snapshot accessible on the IDEXX website, www.idexx.com/investors.

Exceptional commercial execution - including strong volume gains, net

customer expansion, benefits from IDEXX innovation, and growth of the premium instrument installed base - drove double-digit CAG Diagnostics

recurring revenue growth.

▪ IDEXX VetLab™ consumables generated 15% reported and 14% organic revenue growth, supported by testing utilization

gains, including benefits from recent product launches and net new customer growth with 11% expansion of the IDEXX global premium instrument

installed base and net price gains.

▪ Reference laboratory diagnostic and consulting services generated 11% reported and 10% organic revenue growth, driven by higher

testing volumes and net new customer gains.

▪ Rapid assay products revenues increased 1% as reported and on an organic basis, driven by net price benefits and an easing

of the volume impacts from adoption of the Catalyst™ Pancreatic Lipase Test, which has shifted some testing across modalities.

CAG Diagnostics capital instrument revenues decreased 19% as reported

and 20% on an organic basis, lapping the Q2 2025 broad availability of IDEXX inVue Dx, with current-year period revenue benefiting from

over 1,600 IDEXX inVue Dx placements.

Veterinary software, services and diagnostic imaging systems revenues

grew 12% on a reported and organic basis for the quarter, with benefits from cloud-native software growth and installed base expansion.

Diagnostic imaging systems delivered another record quarter of installations, led by ImageVue™ DR50 Plus.

IDEXX Announces Second Quarter Results

August 4, 2026

Page 3 of 17

Water

Water revenues grew 15% as reported and 13% organic for the quarter,

reflecting solid organic growth in the U.S. and Europe.

Livestock, Poultry and Dairy (“LPD”)

LPD revenues increased 11% as reported and 9% organic for the quarter,

led by strong growth in the Americas.

Gross Profit and Operating Profit

Gross profit increased 12% as reported and 11% on a comparable basis.

Gross margin of 64.0% increased 140 basis points as reported and 120 basis points on a comparable basis, supported by strong recurring

revenue volume gains, operational productivity initiatives, and net price realization.

Operating margin was 35.0% for the quarter, higher than the prior year

period by 140 basis points as reported and by 110 basis points on a comparable basis. Operating margin results reflect a 10% operating

expense increase as reported and 9% growth on a comparable basis. Operating expense growth supported expansion of commercial capabilities,

advancement of the Company's innovation agenda, and enabling information technology investments.

2026

Growth and Financial Performance Outlook

The Company is updating its full year revenue growth guidance range

to $4,700 million - $4,745 million, or reported growth of 9.1% - 10.3%, an increase of $5 million at midpoint, net of a $15 million reduction

to projected revenues from a stronger U.S. dollar. The Company is increasing its outlook for organic revenue growth to 8.5% - 9.7%, an

increase of 0.4% at midpoint, reflecting operational performance.

The Company increased its full year reported operating margin outlook

to 32.3% - 32.5%, bringing the projected full year operating profit margin expansion to 70 - 90 basis points as reported and on a comparable

basis. This outlook benefits from strong second quarter operating performance, while advancing strategic investment priorities.

The Company updated its EPS outlook range to $14.69 - $14.94, reflecting

increased reported growth of 12% - 14% and 13% - 15% comparable growth. At midpoint this reflects benefits of $0.14 per share from operational

performance; $0.05 from higher share-based compensation benefits and a $0.05 headwind from updated estimates for foreign exchange impacts.

IDEXX Announces Second Quarter Results

August 4, 2026

Page 4 of 17

The following table provides the Company's updated outlook for annual

key financial metrics in 2026 with a comparison to the prior outlook:

Amounts in millions except per share data and percentages

2026 Growth and Financial Performance Outlook

Updated

Prior

Revenue

$4,700

$4,745

$4,675

$4,760

Reported growth

9.1%

10.3%

8.6%

10.6%

Organic growth

8.5%

9.7%

7.7%

9.7%

CAG Diagnostics Recurring Revenue Growth

Reported growth

10.1%

11.3%

9.6%

11.6%

Organic growth

9.5%

10.7%

8.7%

10.7%

Operating Margin

32.3%

32.5%

32.1%

32.5%

Operating margin expansion

70 bps

90 bps

50 bps

90 bps

Comparable margin expansion

70 bps

90 bps

50 bps

90 bps

EPS

$14.69

$14.94

$14.45

$14.90

Reported growth

12%

14%

11%

14%

Comparable growth

13%

15%

11%

15%

Other Key Metrics

Net interest expense

~ $35

~ $34

Share-based compensation tax benefit

~ $19

~ $15

Share-based compensation tax rate benefit

~ 1.3%

~ 1.0%

Effective tax rate

~ 21.1%

~ 21.4%

Share-based compensation EPS impact

~ $0.24

~ $0.19

Reduction in average shares outstanding

1.5%

Operating Cash Flow (% of Net Income)

110%

120%

105%

115%

Free Cash Flow (% of Net Income)

90%

100%

85%

95%

Capital Expenditures

~ $180

IDEXX Announces Second Quarter Results

August 4, 2026

Page 5 of 17

The following table outlines estimates of foreign currency exchange

rate impacts, net of foreign currency hedging transactions, and foreign currency exchange rate assumptions reflected in the above financial

performance outlook for 2026.

Estimated Foreign Currency Exchange Rate Impacts

2026

Revenue growth rate impact

~0.6%

CAG Diagnostics recurring revenue growth rate impact

~0.6%

Operating margin growth impact

~ 30 bps

EPS impact

~ $0.22

EPS growth impact

~ 2%

Go-Forward Foreign Currency Exchange Rate Assumptions

2026

In U.S. dollars

euro

$1.14

British pound

$1.32

Canadian dollar

$0.70

Australian dollar

$0.69

Relative to the U.S. dollar

Japanese yen

¥162

Chinese renminbi

¥6.80

Brazilian real

R$5.20

Conference Call and Webcast Information

IDEXX

Laboratories, Inc. will host a conference call today at 8:30 a.m. (ET) to discuss its second quarter 2026 results and management’s

outlook. Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors.

An archived edition of the webcast will be available after 1:00 p.m. (ET) via the same link and will remain available for one year.

The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-330-6730 or 1-213-279-1575

and reference passcode 922025.

2026 Investor Day

IDEXX

Laboratories, Inc. will host its 2026 Investor Day on Thursday, August 13, 2026 from 8:00 am to approximately 12:00 pm (ET).

A live webcast and accompanying slide presentations will be available at www.idexx.com/investors. An archived webcast replay

of the event will be available approximately one hour following the event at www.idexx.com/investors. For additional information,

contact investorrelations@idexx.com.

IDEXX Announces Second Quarter Results

August 4, 2026

Page 6 of 17

About IDEXX Laboratories, Inc.

IDEXX

is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly

evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary

community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices.

Our innovations also help measure the safety of milk and water across the world and maintain the health and well-being of people and

livestock. IDEXX Laboratories, Inc. is a member of the S&P 500™ Index. Headquartered in Maine, IDEXX

employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more

information about IDEXX, visit www.idexx.com.

Note Regarding Forward-Looking Statements

This earnings release and the statements to be made in the accompanying

earnings conference call contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including

statements about the Company’s business prospects and estimates of the Company’s financial results for future periods. Forward-looking

statements are included above under "2026 Growth and Financial Performance Outlook" and elsewhere and can be identified by the

use of words such as "expects", "may", "anticipates", "intends", "would", "will",

"plans", "believes", "estimates", "projected", "should", and similar words and expressions.

Our forward-looking statements include statements relating to our expectations regarding financial performance; revenue growth and EPS

outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange rates and interest rates; projected operating

margins and expenses and capital expenditures, including anticipated investments in global commercial capabilities and innovation; projected

tax, tax rate and EPS benefits from share-based compensation arrangements; projected effective tax rates, reduction of average shares

outstanding and net interest expense; trends and other factors impacting the pet healthcare industry, including pet population demographics

and U.S. clinical visits, and their anticipated effects on the Company; IDEXX inVue Dx analyzer placements; IDEXX Cancer Dx testing panel

expansion; rollout of Fine Needle Aspiration to the IDEXX inVue Dx analyzer; and future commercial expansions. These statements are intended

to provide management's expectations or forecasts of future events as of the date of this earnings release; are based on management's

estimates, projections, beliefs, and assumptions as of the date of this earnings release; and are not guarantees of future performance.

These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels

of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements.

These risks and uncertainties include, among other things, the adverse impact, and the duration, of macroeconomic events, conditions,

and uncertainties, such as geopolitical instability (including wars, terrorist attacks, and armed conflicts), general economic uncertainty,

changes in U.S. and other countries’ tariff and trade policies, severe weather and other natural conditions, and supply chain challenges

on our business, results of operations, liquidity, financial condition, and stock price, as well as the matters described under the headings

"Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial

Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company’s

Annual Report on Form 10-K for the year ended December 31, 2025 and in the corresponding sections of the Company's Quarterly

Report on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026, as well as those described from time to time

in the Company’s other filings with the U.S. Securities and Exchange Commission available at www.sec.gov. The Company specifically

disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Statement Regarding Non-GAAP Financial Measures

The following defines terms and conventions and provides reconciliations

regarding certain measures used in this earnings release and/or the accompanying earnings conference call that are not required by, or

presented in accordance with, generally accepted accounting principles in the United States of America ("GAAP"), otherwise referred

to as non-GAAP financial measures. To supplement the Company’s consolidated results presented in accordance with GAAP, the Company

has disclosed non-GAAP financial measures that exclude or adjust certain items. Management believes these non-GAAP financial measures

provide useful supplemental information for its and investors’ evaluation of the Company’s business performance and liquidity

and are useful for period-over-period comparisons of the performance of the Company’s business and its liquidity and to the performance

and liquidity of our peers. While management believes that these non-GAAP financial measures are useful in evaluating the Company’s

business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute

for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the

same as similarly titled measures reported by other companies.

IDEXX Announces Second Quarter Results

August 4, 2026

Page 7 of 17

Constant

currency - Constant currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency

exchange rates and are consistent with how management evaluates our performance and comparisons with prior and future periods. We estimate

the net impacts of currency on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange

rates or exchange rate assumptions for the comparative period, which includes adjusting for the estimated impacts of foreign currency

hedging transactions and certain impacts on our effective tax rates. These estimated currency changes impacted second quarter 2026 results

as follows: increased gross profit growth by 1.1%, increased gross margin expansion 20 basis points, increased operating expense growth

by 0.5%, increased operating profit growth by 1.6%, increased operating profit margin growth by 30 basis points, and increased EPS growth

by 1.7%. Constant currency revenue growth represents the percentage change in revenue during the applicable period, as compared to the

prior year period, excluding the impact of changes in foreign currency exchange rates. See the supplementary analysis of results below

for revenue percentage change from currency for the three and six months ended June 30, 2026 and refer to the 2026 Growth and Financial

Performance Outlook section of this earnings release for estimated foreign currency exchange rate impacts on 2026 projections and estimates.

Growth

and organic revenue growth - All references to growth and organic growth refer to growth compared to the equivalent prior year

period unless specifically noted. Organic revenue growth is a non-GAAP financial measure that represents the percentage change in revenue,

as compared to the same period for the prior year, net of the effect of changes in foreign currency exchange rates, certain business acquisitions,

and divestitures. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier

comparisons of our revenue performance with prior and future periods and to the performance of our peers. Organic revenue growth should

be considered in addition to, and not as a replacement of or a superior measure to, revenue growth reported in accordance with GAAP. See

the supplementary analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three and

six months ended June 30, 2026. Please refer to the constant currency note above for a summary of foreign currency exchange rate

impacts. Please refer to the 2026 Growth and Financial Performance Outlook section of this earnings release for estimated full year 2026

organic revenue growth for the Company and CAG Diagnostics recurring revenue growth. The percentage change in revenue resulting from acquisitions

represents revenues during the current year period, limited to the initial 12 months from the date of the acquisition, that are directly

attributable to business acquisitions. Revenue from acquisitions is expected to have an immaterial impact on projected full year 2026

revenue growth and no impact on CAG Diagnostics recurring revenue growth.

We exclude from organic revenue growth the effect of changes in foreign

currency exchange rates because changes in foreign currency exchange rates are not under management’s control, are subject to volatility,

and can obscure underlying business trends. We calculate the impact on revenue resulting from changes in foreign currency exchange rates

by applying the difference between the weighted average exchange rates during the current year period and the comparable prior year period

to foreign currency denominated revenues for the prior year period.

We also exclude from organic revenue growth the effect of certain business

acquisitions and divestitures because the nature, size, and number of these transactions can vary dramatically from period to period,

and because they either require or generate cash as an inherent consequence of the transaction, and therefore can also obscure underlying

business and operating trends. We consider acquisitions to be a business when all three elements of inputs, processes, and outputs are

present, consistent with ASU 2017-01, “Business Combinations: (Topic 805) Clarifying the Definition of a Business.”

We do not consider acquired assets to be a business if substantially all the fair value of the assets acquired is concentrated in a single

identifiable asset or group of similar identifiable assets. A typical acquisition that we do not consider a business is a customer relationship

asset acquisition, which does not have all elements necessary to operate a business, such as employees or infrastructure. Revenue from

these customers acquired is included in organic revenue growth because we believe the efforts required to convert and retain these acquired

customers are similar in nature to our efforts to obtain and retain our existing customer base.

Comparable

growth metrics - Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth,

comparable operating profit growth and comparable operating margin gain (or growth) are non-GAAP financial measures and exclude the impact

of changes in foreign currency exchange rates and non-recurring or unusual items (if any). Please refer to the constant currency note

above for a summary of foreign currency exchange rate impacts. Management believes that reporting comparable gross profit growth, comparable

gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin

gain (or growth) provides useful information to investors because it enables better period-over-period comparisons of the fundamental

financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding key

metrics used by management. Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth,

comparable operating profit growth and comparable operating margin gain (or growth) should be considered in addition to, and not as replacements

of or superior measures to, gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin

gain reported in accordance with GAAP.

IDEXX Announces Second Quarter Results

August 4, 2026

Page 8 of 17

The reconciliation of these non-GAAP financial measures is as follows:

Three Months

Ended

Year-over-Year

Six Months

Ended

Year-over-Year

June 30,

Change

June 30,

Change

Dollar amounts in thousands

2026

2025

2026

2025

Gross profit and growth (as reported)

$ 779,087

$ 694,732

12 %

$ 1,501,826

$ 1,318,111

14 %

Gross margin and margin gain

64.0 %

62.6 %

140 bps

63.7 %

62.5 %

120 bps

Less: comparability adjustments

Change from currency

7,511

—

27,982

—

Comparable gross profit and growth

$ 771,576

$ 694,732

11 %

$ 1,473,844

$ 1,318,111

12 %

Comparable gross margin and margin gain

63.9 %

62.6 %

120 bps

63.6 %

62.5 %

110 bps

Operating expenses and growth (as reported)

$ 353,521

$ 321,686

10 %

$ 713,674

$ 628,531

14 %

Less: comparability adjustments

Change from currency

1,458

—

7,728

—

Loss on equity investment

—

5,000

—

Now-concluded litigation matter

—

(8,600 )

Comparable operating expense and growth

$ 352,063

$ 321,686

9 %

$ 700,946

$ 637,131

10 %

Operating profit and growth (as reported)

$ 425,566

$ 373,046

14 %

$ 788,152

$ 689,580

14 %

Operating margin and margin gain

35.0 %

33.6 %

140 bps

33.4 %

32.7 %

70 bps

Less: comparability adjustments

Change from currency

6,053

—

20,254

—

Loss on equity investment

—

(5,000 )

—

Now-concluded litigation matter

—

8,600

Comparable operating profit and growth

$ 419,513

$ 373,046

12 %

$ 772,898

$ 680,980

13 %

Comparable operating margin and margin gain

34.7 %

33.6 %

110 bps

33.3 %

32.3 %

100 bps

Amounts presented may not recalculate due to rounding.

Projected 2026 comparable operating margin expansion outlined in the

2026 Growth and Financial Performance Outlook section of this earnings release reflects the following adjustments: (i) full year

2026 reported operating margin adjusted for a $5 million unfavorable impact of loss on an equity investment; (ii) adjustment to projected

2026 operating margin for a positive impact from year-over-year foreign currency exchange rate changes at noted exchange rates; and (iii) adjustment

to 2025 operating margin for the positive impact of the approximately $9 million discrete litigation expense accrual adjustment in the

second quarter of 2025.

These impacts described above reconcile reported gross profit growth,

gross margin gain, operating expense growth, operating profit growth and operating margin gain (including projected 2026) to comparable

gross profit growth, comparable gross margin gain, comparable operating expense growth, comparable operating profit growth and comparable

operating margin gain for the Company.

IDEXX Announces Second Quarter Results

August 4, 2026

Page 9 of 17

Comparable

EPS growth - Comparable EPS growth is a non-GAAP financial measure that represents the percentage change in earnings per share

(diluted) ("EPS") for a measurement period, as compared to the prior base period, net of the impact of changes in foreign currency

exchange rates from the prior base period and excluding the tax benefits of share-based compensation activity under ASU 2016-09, "Compensation-Stock

Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting," and non-recurring or unusual items (if any).

Management believes comparable EPS growth is a more useful way to measure the Company’s business performance than EPS growth because

it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance

and provides greater transparency to investors regarding a key metric used by management. Comparable EPS growth should be considered in

addition to, and not as a replacement of or a superior measure to, EPS growth reported in accordance with GAAP. Please refer to the constant

currency note above for a summary of foreign currency exchange rate impacts.

The reconciliation of this non-GAAP financial measure is as follows:

Three Months Ended

Year-over-Year

Six Months Ended

Year-over-Year

June 30,

Growth

June 30,

Growth

2026

2025

2026

2025

Earnings per share (diluted) and growth

$ 4.27

$ 3.63

18 %

$ 7.74

$ 6.59

17 %

Less: comparability adjustments

Share-based compensation activity

0.14

0.10

0.23

0.11

Loss on equity investment

—

(0.05 )

—

Now-concluded litigation matter

—

0.08

Change from currency

0.06

—

0.20

—

Comparable EPS and growth

$ 4.07

$ 3.53

15 %

$ 7.36

$ 6.40

15 %

Amounts presented may not recalculate due to rounding.

Projected 2026 comparable EPS growth outlined in the 2026 Growth and

Financial Performance Outlook section of this earnings release reflects the following adjustments: (i) adjustment to projected full

year 2026 reported EPS for estimated positive year-over-year foreign currency exchange rate change impact of $0.22 at noted exchange rates;

(ii) adjustment to projected full year 2026 reported EPS for estimated positive impact of share-based compensation activity of $0.24;

(iii) adjustment to projected full year 2026 EPS of $0.05 for unfavorable impact of a loss on an equity investment; (iv) adjustment

to full year 2025 reported EPS for a positive $0.08 impact from the discrete litigation expense accrual adjustment in the second quarter

of 2025; and (v) adjustment to full year 2025 reported EPS for positive impact of share-based compensation activity of $0.35.

These impacts and those described in the constant currency note above

reconcile reported EPS growth (including projected 2026 reported EPS growth) to comparable EPS growth for the Company.

Segment

and Other Income from Operations - We report segment income from operations in our Segment Information table below. Segment

income from operations is a non-GAAP financial measure that adjusts for the impact of foreign currency transaction gains and losses and

should be considered in addition to, and not as a replacement for, or superior measure to, income from operations. We exclude foreign

currency transaction gains and losses for each reportable segment (CAG, Water, and LPD) from segment income from operations and report

the full amount of foreign currency transaction gains and losses in Other. We believe that reporting segment income from operations provides

supplemental analysis to help investors further evaluate each reportable segment’s business performance by excluding foreign currency

transaction gains and losses, which are centrally managed by our corporate treasury function and which we do not consider relevant for

assessing the results of each reportable segment’s operations. In addition, we believe that reporting segment income from operations

provides information to investors regarding key metrics that are used by management, including our chief operating decision-maker, in

evaluating the performance of each reportable segment.

The reconciliation of this non-GAAP financial measure is as follows

for the three and six months ended June 30, 2026 and 2025:

Amounts in thousands

Three Months Ended June 30,

2026

2025

Income from

Operations

Impact from

Foreign

Currency

Segment and

Other Income

from

Operations

Income from

Operations

Impact from

Foreign

Currency

Segment and

Other Income

from

Operations

CAG

$ 393,069

$ 214

$ 393,283

$ 347,983

$ 494

$ 348,477

Water

30,258

30,274

24,606

24,642

LPD

2,395

2,411

(543 )

(505 )

Other

(156 )

(246 )

(402 )

1,000

(568 )

432

Total

$ 425,566

$ —

$ 425,566

$ 373,046

$ —

$ 373,046

IDEXX Announces Second Quarter Results

August 4, 2026

Page 10 of 17

Amounts in thousands

Six Months Ended June 30,

2026

2025

Income from

Operations

Impact from

Foreign

Currency

Segment and

Other Income

from

Operations

Income from

Operations

Impact from

Foreign

Currency

Segment and

Other Income

from

Operations

CAG

$ 730,234

$ 604

$ 730,838

$ 642,554

$ 1,078

$ 643,632

Water

53,901

53,943

45,380

45,459

LPD

3,657

3,701

(462 )

(380 )

Other

360

(690 )

(330 )

2,108

(1,239 )

869

Total

$ 788,152

$ —

$ 788,152

$ 689,580

$ —

$ 689,580

Free cash

flow - Free cash flow is a non-GAAP financial measure and means, with respect to a measurement period, the cash generated from

operations during that period, reduced by the Company’s investments in property and equipment. Management believes free cash flow

is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring

investments in property and equipment that are required to operate the business. Free cash flow should be considered in addition to, and

not as a replacement of or a superior measure to, net cash provided by operating activities. See the supplementary analysis of results

below for our calculation of free cash flow for the three and six months ended June 30, 2026 and 2025. To estimate projected 2026

free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of approximately

$180 million. Free cash flow conversion, or the net income to free cash flow ratio, is a non-GAAP financial measure that is defined as

free cash flow, with respect to a measurement period, divided by net income for the same period. To calculate trailing twelve-month net

income to free cash flow ratio for the twelve months ended June 30, 2026, we have deducted purchases of property and equipment of

approximately $117 million from net cash provided from operating activities of approximately $1,372 million, divided by net income of

approximately $1,140 million.

Debt

to Adjusted EBITDA (Leverage Ratios) - Adjusted EBITDA, gross debt, and net debt are non-GAAP financial measures.

Adjusted EBITDA is a non-GAAP financial measure of earnings before interest, taxes, depreciation, amortization, non-recurring

transaction expenses incurred in connection with acquisitions, share-based compensation expense, and certain other non-cash losses

and charges. Management believes that reporting Adjusted EBITDA, gross debt, and net debt in the Debt to Adjusted EBITDA ratios

provides supplemental analysis to help investors further evaluate the Company's business performance and available borrowing

capacity under the Company's credit facility. Adjusted EBITDA, gross debt, and net debt should be considered in addition to, and not

as replacements of or superior measures to, net income or total debt reported in accordance with GAAP. For further information on

how Adjusted EBITDA and the Debt to Adjusted EBITDA Ratios are calculated, see the Company's Annual Report on Form 10-K for the

year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

Notes and Definitions

Discrete

litigation expense accrual - During the first quarter of 2025, the Company reduced its previously established $89.0 million

accrual related to a concluded litigation matter by approximately $9 million, which represented our best estimate at that time of the

amount of the loss.

Concluded

litigation matter - The Company was a defendant in a litigation matter involving an alleged breach of contract for underpayment

of royalty payments made from 2004 through 2017 under an expired patent license agreement, and the trial court ruled in favor of the plaintiff

in 2020. Following appeals and in light of the appellate court's April 3, 2025 decision, on April 17, 2025, the Company paid

the judgment of approximately $80 million, and the plaintiff executed a satisfaction and release of judgment, which was filed with the

trial court on the same date, concluding this matter. For further information, see the Company's Quarterly Report on Form 10-Q for

the quarter ended June 30, 2026.

IDEXX Announces Second Quarter Results

August 4, 2026

Page 11 of 17

IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Statement of Operations

Amounts in thousands except per share data (Unaudited)

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Revenue:

Revenue

$ 1,216,585

$ 1,109,457

$ 2,357,405

$ 2,107,884

Expenses and Income:

Cost of revenue

437,498

414,725

855,579

789,773

Gross profit

779,087

694,732

1,501,826

1,318,111

Sales and marketing

171,277

161,107

346,527

317,330

General and administrative

116,815

98,681

235,930

190,242

Research and development

65,429

61,898

131,217

120,959

Total operating expense

353,521

321,686

713,674

628,531

Income from operations

425,566

373,046

788,152

689,580

Non-operating income (expense), net

(8,342 )

(10,694 )

(15,486 )

(17,144 )

Income before provision for income taxes

417,224

362,352

772,666

672,436

Provision for income taxes

78,812

68,363

155,808

135,770

Net Income:

Net income attributable to stockholders

$ 338,412

$ 293,989

$ 616,858

$ 536,666

Earnings per share: Basic

$ 4.29

$ 3.66

$ 7.78

$ 6.64

Earnings per share: Diluted

$ 4.27

$ 3.63

$ 7.74

$ 6.59

Shares outstanding: Basic

78,954

80,413

79,299

80,864

Shares outstanding: Diluted

79,312

80,994

79,742

81,465

IDEXX Laboratories, Inc. and Subsidiaries

Selected Operating Information (Unaudited)

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Operating Ratios

Gross profit

64.0 %

62.6 %

63.7 %

62.5 %

(as a percentage of revenue):

Sales, marketing, general and administrative expense

23.7 %

23.4 %

24.7 %

24.1 %

Research and development expense

5.4 %

5.6 %

5.7 %

Income from operations1

35.0 %

33.6 %

33.4 %

32.7 %

1Amounts presented

may not recalculate due to rounding.

IDEXX Announces Second Quarter Results

August 4, 2026

Page 12 of 17

IDEXX Laboratories, Inc. and Subsidiaries

Segment and Other Information

Amounts in thousands (Unaudited)

Three Months Ended

June 30, 2026

Percent of

Revenue

June 30, 2025

Percent of

Revenue

Revenue:

CAG

$ 1,118,236

$ 1,022,443

Water

58,564

51,001

LPD

35,181

31,762

Other

4,604

4,251

Total

$ 1,216,585

$ 1,109,457

Gross Profit:

CAG

$ 715,787

64.0 %

$ 642,102

62.8 %

Water

43,598

74.4 %

35,511

69.6 %

LPD

18,651

53.0 %

14,929

47.0 %

Other

1,051

22.8 %

2,190

51.5 %

Total

$ 779,087

64.0 %

$ 694,732

62.6 %

Income from Operations:

CAG

$ 393,283

35.2 %

$ 348,477

34.1 %

Water

30,274

51.7 %

24,642

48.3 %

LPD

2,411

6.9 %

(505 )

(1.6 )%

Other

(402 )

(8.7 )%

432

10.2 %

Total

$ 425,566

35.0 %

$ 373,046

33.6 %

Six Months

Ended

June 30, 2026

Percent of

Revenue

June 30, 2025

Percent of

Revenue

Revenue:

CAG

$ 2,172,288

$ 1,942,279

Water

108,829

96,322

LPD

67,664

60,358

Other

8,624

8,925

Total

$ 2,357,405

$ 2,107,884

Gross Profit:

CAG

$ 1,383,296

63.7 %

$ 1,216,925

62.7 %

Water

80,135

73.6 %

67,584

70.2 %

LPD

35,561

52.6 %

29,294

48.5 %

Other

2,834

32.9 %

4,308

48.3 %

Total

$ 1,501,826

63.7 %

$ 1,318,111

62.5 %

Income from Operations:

CAG

$ 730,838

33.6 %

$ 643,632

33.1 %

Water

53,943

49.6 %

45,459

47.2 %

LPD

3,701

5.5 %

(380 )

(0.6 )%

Other

(330 )

(3.8 )%

869

9.7 %

Total

$ 788,152

33.4 %

$ 689,580

32.7 %

IDEXX Announces Second Quarter Results

August 4, 2026

Page 13 of 17

IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets

Amounts in thousands (Unaudited)

Three Months Ended

Net Revenue

June 30,

2026

June 30,

2025

Dollar

Change

Reported

Revenue

Growth1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth1

CAG

$ 1,118,236

$ 1,022,443

$ 95,793

9.4 %

0.6 %

—

8.7 %

United States

734,892

684,497

50,395

7.4 %

—

7.4 %

International

383,344

337,946

45,398

13.4 %

1.9 %

—

11.5 %

Water

$ 58,564

$ 51,001

$ 7,563

14.8 %

1.9 %

—

13.0 %

United States

29,621

26,090

3,531

13.5 %

—

13.5 %

International

28,943

24,911

4,032

16.2 %

3.8 %

—

12.4 %

LPD

$ 35,181

$ 31,762

$ 3,419

10.8 %

1.8 %

—

9.0 %

United States

6,608

5,767

841

14.6 %

—

14.6 %

International

28,573

25,995

2,578

9.9 %

2.1 %

—

7.8 %

Other

$ 4,604

$ 4,251

$ 353

8.3 %

—

8.3 %

Total Company

$ 1,216,585

$ 1,109,457

$ 107,128

9.7 %

0.7 %

—

9.0 %

United States

772,968

717,869

55,099

7.7 %

—

7.7 %

International

443,617

391,588

52,029

13.3 %

2.0 %

—

11.2 %

Three Months Ended

Net CAG Revenue

June 30,

2026

June 30,

2025

Dollar

Change

Reported

Revenue

Growth1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth1

CAG Diagnostics recurring revenue:

$ 974,713

$ 877,995

$ 96,718

11.0 %

0.7 %

—

10.3 %

IDEXX VetLab consumables

430,337

375,112

55,225

14.7 %

1.1 %

—

13.6 %

Rapid assay products

101,575

100,240

1,335

1.3 %

0.3 %

—

1.1 %

Reference laboratory diagnostic and consulting services

406,729

367,694

39,035

10.6 %

0.3 %

—

10.3 %

CAG Diagnostics services and accessories

36,072

34,949

1,123

3.2 %

1.1 %

—

2.1 %

CAG Diagnostics capital – instruments

$ 47,174

$ 58,600

($ 11,426 )

(19.5 %)

0.1 %

—

(19.6 %)

Veterinary software, services and diagnostic imaging systems:

$ 96,349

$ 85,848

$ 10,501

12.2 %

0.4 %

—

11.8 %

Recurring revenue

76,343

68,954

7,389

10.7 %

0.5 %

—

10.2 %

Systems and hardware

20,006

16,894

3,112

18.4 %

0.2 %

—

18.2 %

Net CAG revenue

$ 1,118,236

$ 1,022,443

$ 95,793

9.4 %

0.6 %

—

8.7 %

Three Months Ended

June 30, 2026

June 30, 2025

Dollar

Change

Reported

Revenue

Growth1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth1

CAG Diagnostics recurring revenue:

$ 974,713

$ 877,995

$ 96,718

11.0 %

0.7 %

—

10.3 %

United States

630,504

575,009

55,495

9.7 %

—

9.7 %

International

344,209

302,986

41,223

13.6 %

2.0 %

—

11.6 %

1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

IDEXX Announces Second Quarter Results

August 4, 2026

Page 14 of 17

IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets

Amounts in thousands (Unaudited)

Six Months Ended

Net Revenue

June 30, 2026

June 30, 2025

Dollar

Change

Reported

Revenue

Growth1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth1

CAG

$ 2,172,288

$ 1,942,279

$ 230,009

11.8 %

1.7 %

—

10.1 %

United States

1,425,792

1,308,386

117,406

9.0 %

—

9.0 %

International

746,496

633,893

112,603

17.8 %

5.4 %

—

12.4 %

Water

$ 108,829

$ 96,322

$ 12,507

13.0 %

2.8 %

—

10.2 %

United States

56,014

49,593

6,421

12.9 %

—

12.9 %

International

52,815

46,729

6,086

13.0 %

5.6 %

—

7.4 %

LPD

$ 67,664

$ 60,358

$ 7,306

12.1 %

4.0 %

—

8.2 %

United States

12,992

11,555

1,437

12.4 %

—

12.4 %

International

54,672

48,803

5,869

12.0 %

4.8 %

—

7.2 %

Other

$ 8,624

$ 8,925

($ 301 )

(3.4 %)

—

(3.4 %)

Total Company

$ 2,357,405

$ 2,107,884

$ 249,521

11.8 %

1.8 %

—

10.0 %

United States

1,498,200

1,372,730

125,470

9.1 %

—

9.1 %

International

859,205

735,154

124,051

16.9 %

5.3 %

—

11.6 %

Six Months Ended

Net CAG Revenue

June 30, 2026

June 30, 2025

Dollar

Change

Reported

Revenue

Growth1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth1

CAG Diagnostics recurring revenue:

$ 1,895,026

$ 1,684,262

$ 210,764

12.5 %

1.8 %

—

10.7 %

IDEXX VetLab consumables

842,919

719,891

123,028

17.1 %

2.6 %

—

14.5 %

Rapid assay products

186,513

184,274

2,239

1.2 %

0.7 %

—

0.5 %

Reference laboratory diagnostic and consulting services

792,908

712,100

80,808

11.3 %

1.4 %

—

10.0 %

CAG Diagnostics services and accessories

72,686

67,997

4,689

6.9 %

2.3 %

—

4.6 %

CAG Diagnostics capital – instruments

$ 89,623

$ 90,594

($ 971 )

(1.1 %)

1.4 %

—

(2.5 %)

Veterinary software, services and diagnostic imaging systems:

$ 187,639

$ 167,423

$ 20,216

12.1 %

0.7 %

—

11.4 %

Recurring revenue

149,879

134,747

15,132

11.2 %

0.8 %

—

10.5 %

Systems and hardware

37,760

32,676

5,084

15.6 %

0.3 %

—

15.2 %

Net CAG revenue

$ 2,172,288

$ 1,942,279

$ 230,009

11.8 %

1.7 %

—

10.1 %

Six Months Ended

June 30, 2026

June 30, 2025

Dollar

Change

Reported

Revenue

Growth1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth1

CAG Diagnostics recurring revenue:

$ 1,895,026

$ 1,684,262

$ 210,764

12.5 %

1.8 %

—

10.7 %

United States

1,224,987

1,111,986

113,002

10.2 %

—

10.2 %

International

670,039

572,276

97,762

17.1 %

5.4 %

—

11.6 %

1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

IDEXX Announces Second Quarter Results

August 4, 2026

Page 15 of 17

IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Balance Sheet

Amounts in thousands (Unaudited)

June 30, 2026

December 31, 2025

Assets:

Current Assets:

Cash and cash equivalents

$ 196,933 $

180,070

Accounts receivable, net

627,083

552,378

Inventories

391,579

377,756

Other current assets

293,894

303,623

Total current assets

1,509,489

1,413,827

Property and equipment, net

733,238

747,380

Other long-term assets, net

1,199,608

1,189,552

Total assets

$ 3,442,335 $

3,350,759

Liabilities and Stockholders'

Equity:

Current Liabilities:

Accounts payable

$ 129,097

$110,408

Accrued liabilities

453,169

530,147

Line of credit

519,000

398,000

Current portion of long-term debt

149,999

74,995

Deferred revenue

36,400

35,264

Total current liabilities

1,287,665

1,148,814

Long-term debt, net of current portion

299,865

374,842

Other long-term liabilities, net

242,230

221,720

Total long-term liabilities

542,095

596,562

Total stockholders' equity

1,612,575

1,605,383

Total liabilities and stockholders' equity

$ 3,442,335 $

3,350,759

IDEXX Laboratories, Inc. and Subsidiaries

Selected Balance Sheet Information (Unaudited)

June 30,

2026

March 31,

2026

December 31,

2025

September 30,

2025

June 30,

2025

Selected Balance Sheet Information:

Days sales outstanding1

46.2

46.8

46.5

44.7

Inventory turns2

1.4

1.6

1.5

1Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days.

2Inventory turns are calculated as the ratio of our inventory-related cost of revenue for the quarter multiplied by four, divided by the average inventory balances at the beginning and end of each quarter.

IDEXX Announces Second Quarter Results

August 4, 2026

Page 16 of 17

IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Statement of Cash Flows

Amounts in thousands (Unaudited)

Six Months Ended

June 30, 2026

June 30, 2025

Operating:

Cash Flows from Operating Activities:

Net income

$ 616,858

$ 536,666

Non-cash adjustments to net income

143,240

111,582

Changes in assets and liabilities

(146,688 )

(224,543 )

Net cash provided by operating activities

613,410

423,705

Investing:

Cash Flows from Investing Activities:

Purchases of property and equipment

(56,630 )

(64,128 )

Acquisitions

(4,491 )

—

Proceeds from net investment hedges

2,081

890

Net cash used by investing activities

(59,040 )

(63,238 )

Financing:

Cash Flows from Financing Activities:

Borrowings under credit facility, net

121,000

329,000

Payments of senior notes

—

(103,386 )

Repurchases of common stock

(697,840 )

(738,995 )

Proceeds from exercises of stock options and employee stock purchase plans

51,074

24,523

Shares withheld for statutory tax withholding payments on restricted stock

(10,853 )

(7,094 )

Net cash used by financing activities

(536,619 )

(495,952 )

Net effect of changes in exchange rates on cash

(888 )

11,813

Net increase (decrease) in cash and cash equivalents

16,863

(123,672 )

Cash and cash equivalents, beginning of period

180,070

288,266

Cash and cash equivalents, end of period

$ 196,933

$ 164,594

IDEXX Laboratories, Inc. and Subsidiaries

Free Cash Flow

Amounts in thousands (Unaudited)

Three Months Ended

Six Months Ended

June 30, 2026

June 30, 2025

June 30, 2026

June 30, 2025

Free Cash Flow:

Net cash provided by operating activities

$ 347,162

$ 185,743

$ 613,410

$ 423,705

Investing cash flows attributable to purchases of property and equipment

(24,646 )

(34,102 )

(56,630 )

(64,128 )

Free cash flow1

$ 322,516

$ 151,641

$ 556,780

$ 359,577

1See Statement

Regarding Non-GAAP Financial Measures, above.

IDEXX Announces Second Quarter Results

August 4, 2026

Page 17 of 17

IDEXX Laboratories, Inc. and Subsidiaries

Common Stock Repurchases

Amounts in thousands except per share data (Unaudited)

Three Months Ended

Six Months Ended

June 30, 2026

June 30, 2025

June 30, 2026

June 30, 2025

Shares repurchased in the open market

582

713

1,170

1,644

Shares acquired through employee surrender for statutory tax withholding

—

Total shares repurchased

582

715

1,187

1,660

Cost of shares repurchased in the open market

$ 332,046

$ 327,530

$ 692,879

$ 736,745

Cost of shares for employee surrenders

298

970

10,853

7,094

Total cost of shares

$ 332,344

$ 328,500

$ 703,732

$ 743,839

Average cost per share – open market repurchases

$ 570.72

$ 458.96

$ 592.41

$ 448.02

Average cost per share – employee surrenders

$ 563.62

$ 513.46

$ 627.34

$ 452.84

Average cost per share – total

$ 570.71

$ 459.10

$ 592.92

$ 448.07

GRAPHIC

Filename: tm2622041d1_8kimg01.jpg · Sequence: 6

Binary file (2376 bytes)

Download tm2622041d1_8kimg01.jpg

GRAPHIC

Filename: tm2622041d1_ex99-1img01.jpg · Sequence: 7

Binary file (5160 bytes)

Download tm2622041d1_ex99-1img01.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Aug. 04, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 04, 2026

Entity File Number

000-19271

Entity Registrant Name

IDEXX LABORATORIES INC /DE

Entity Central Index Key

0000874716

Entity Tax Identification Number

01-0393723

Entity Incorporation, State or Country Code

Entity Address, Address Line One

One IDEXX Drive

Entity Address, City or Town

Westbrook

Entity Address, State or Province

Entity Address, Postal Zip Code

04092

City Area Code

207

Local Phone Number

556.0300

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.10 par value per share

Trading Symbol

IDXX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration